Experts discuss challenges and novel approaches in lower- and higher-risk MDS including red blood cell transfusion dependence, failure of EASAs, and potential treatment options. Emphasis on the need for more agents and combinations. They also explore alternative options, clinical trials, and personalized treatment for high-risk MDS. Results of a phase two trial using monoclonal antibody Sabotolomab show improved response and longer progression-free survival.